Lead Product(s): Non-opioid drug
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: March of Dimes
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Funding June 04, 2020
The current Innovative Challenge Grant allows Katana Pharmaceutical to develop a novel non-opioid treatment for neonatal abstinence syndrome (NAS).